MRK

$119.72

Public overview and default valuation.

Log in to track this stock.

Valuation Details
Default assumptions: 10Y forecast, 9% market return, 2.5% terminal growth, 3.86% trendline growth.
Want to create your own valuation? Create a free account.
$297.94

With 20% Margin of Safety (MoS):

$238.35
99.10% upside
Capital Efficiency
Average Quarterly ROIC
9.18%
Cost of Capital (estimated)9%
Value StatusCreating Value

The company is earning a higher return on invested capital than it costs to raise that capital — a sign of strong, efficient value creation.

Complete historical ROIC is available with
.
Fundamental Score
71
BullishWeighted across 6 signals
DCF Discount
99.1% discount to price
100
FCF Yield
7.0% trailing FCF yield
100
ROIC vs WACC
ROIC 9.2% vs WACC 9.0% (1.0x)
51
Net Debt / FCF
Net cash position
100
Buybacks
Share count shrinking
80
FCF CAGR (5Y)
4.5% 5Y FCF CAGR
25
Strengths: DCF Discount, FCF Yield. Concerns: FCF CAGR (5Y).
Narrative Score
65
Improving
Weighted across 6 recent drivers · Last 30 days-3 vs previous · +2 new driversVs 6-Month Baseline: Below Avg (24th pct)
Trend: Deteriorating downConfidence: 100%Updated: 5h ago
Sources: 215 (News 200 · Analyst 15)
Drivers
132 news sentiment+0.9
4 earnings beat+0.5
60 regulatory scrutiny+0.1
2 legal risk+0.1
3 analyst upgrades+0.0
2 upgrade headlines+0.0
Other Metrics
P/E15.2
Profit Margin29.6%
Owner Earnings$31.96b
One Dollar Premise37.00%
Debt/Equity1.45
Current Ratio1.47
PEG0.927
Free Cash Flow (in millions)
20052006200720082009201020112012201320142015201620172018201920202021202220232024
$9,011$7,745$8,010$7,870$4,853$12,500$14,106$11,976$13,202$10,177$13,704$11,990$8,335$13,537$16,913$14,937$18,557$23,483$16,869$21,081
How Intrinziq Estimates Fair Value

Intrinziq estimates Merck & Co., Inc.'s intrinsic value using a discounted cash flow (DCF) model based on free cash flow trends and a market-based discount rate. The model projects future cash flows over ten years and discounts them using a market return assumption to estimate fair value.

Merck & Co., Inc.Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Last updated: Feb 06, 2026
Data sources: Financial Modeling Prep
This valuation is based on assumptions and publicly available data. It is not financial advice or a recommendation to buy or sell any security. Always do your own research before making investment decisions.